Viewing nowSelpam Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 202105908 · Approved 2021.08.11 · Insurance code 693904030
Improves glycemic control in adults with type 2 diabetes
This medication is used in combination with dietary and exercise therapy to improve blood sugar control for adult patients with type 2 diabetes. It can be administered alone or in combination with other medications. Caution is needed when used in patients with type 2 diabetes who have cardiovascular disease and are not sufficiently controlling blood sugar; for detailed information, please refer to the clinical trial information for professionals. This medication helps improve blood sugar control and assists in diabetes management.
The recommended dose of this medicine is 10 mg once daily, as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used by patients who have allergic reactions to the active ingredient or any component. This medication should not be administered to type 1 diabetes patients or those with diabetic ketoacidosis. It is not recommended for patients with significantly impaired kidney function, that is, with a glomerular filtration rate of less than 30 mL/min/1.73 m², or those with end-stage renal disease, or those undergoing dialysis. This medication contains lactose, so it should not be administered to patients with genetic metabolic disorders such as lactose intolerance or galactose intolerance. It should be used cautiously in patients with slightly impaired kidney function, and if kidney function continues to deteriorate, dosage adjustment or discontinuation of the medication may be necessary. In cases of mild to moderate heart failure, it should be used cautiously, and it is not recommended for patients with severe heart failure. When used in combination with insulin or sulfonylureas, there may be an increased risk of hypoglycemia, so dosage adjustments may be necessary. The most common side effect of this medication is hypoglycemia, and caution is needed, especially when used with other antidiabetic medications. Genital or urinary tract infections may occur, and immediate treatment is necessary if symptoms appear. Increased urination may occur, which can lead to discomfort. There is a risk of decreased blood volume leading to lowered blood pressure or dehydration, so elderly patients or those with hypotension should be cautious. Serious metabolic abnormalities such as ketoacidosis may occur; if symptoms such as vomiting, abdominal pain, or difficulty breathing appear, immediate hospital visit is required. There have been reported cases of liver damage; if symptoms of liver dysfunction appear, the patient should consult a physician. This medication may have a mild effect on driving or operating machinery, so caution is especially needed if there is a risk of hypoglycemia. Use of this medication during pregnancy is not recommended, and it should be discontinued if pregnancy is confirmed. If breastfeeding, it is advisable to discontinue breastfeeding due to the possibility of this medication being excreted in breast milk. The safety and efficacy of this medication in children and adolescents under 18 years have not been established. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment is necessary depending on the clinical condition. This medication should be kept out of reach of children and should not be transferred to other containers. During the use of this medication, it is important to regularly monitor kidney function, and to consult medical personnel immediately if any abnormal symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best to store the medication at room temperature between 1 and 30 degrees Celsius, avoiding extremely hot or cold conditions.
Light yellow round film-coated tablet
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.